可选产品分析
经您允许，我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Expansion of specialty biopharmaceutical distribution and oncology practice management services, exemplified by the definitive agreement to acquire American Oncology Network.
Accelerated store closure program or credit distress at anchor customer Walgreens Boots Alliance, reducing contracted wholesale volume below baseline expectations.
We maintain a Hold rating on Cencora, Inc. (NYSE: COR) with an intrinsic fair value of $328.59 per share, compared to a market price of $340.43 as of October 21, 2026, representing an upside of -3.5%.4
Cencora is an essential cog in the United States healthcare infrastructure, distributing roughly one-third of all prescription pharmaceuticals. Through its core U.S. Healthcare Solutions segment, which generated $290.98B in revenue for fiscal 2025, Cencora benefits from steady prescription volume growth, expanding distribution of complex specialty drugs and GLP-1 treatments, and stable fee schedules across the national wholesale triopoly. For fiscal 2026, reported diluted EPS reached $13.31, while the company announced an agreement to acquire American Oncology Network for $2.4B enterprise value, demonstrating continued expansion into higher-margin provider services.
However, the investment case is tightly constrained by valuation and acute customer concentration. Shares trade at $340.43, sitting slightly above our synthesized fair value of $328.59. Moreover, Walgreens Boots Alliance accounts for approximately 25% of consolidated revenue and 38% of accounts receivable net of incentives. Non-prime Walgreens volume began moving outside Cencora on July 1, 2026, and ongoing retail store closures present structural headwinds. Alongside $14.46B in total debt, these factors balance long-term compounding upside, justifying our Hold stance.47
Cencora distributes approximately one-third of US pharmaceuticals, generating $290.98B in domestic healthcare revenue in FY2025. Entrenched infrastructure and cold-chain scale create formidable barriers to entry in a rational three-firm wholesale oligopoly.7
The business generated $3.21B in free cash flow in FY2025, enabling continuous share repurchases that retired over 4.38M shares between FY2025 and October 2026, comfortably exceeding stock-based compensation of $147.96M.456
The definitive agreement to acquire American Oncology Network adds extensive oncology provider practices across multiple states, enhancing physician MSO capabilities and accelerating specialty distribution growth.
Cencora is a high-quality compounder operating within an entrenched triopoly, generating $3.21B in free cash flow in FY2025 and reporting diluted EPS of $13.31 in FY2026. However, with shares trading at $340.43 slightly above fair value of $328.59, and with significant customer concentration in Walgreens Boots Alliance (25% of revenue, 38% of receivables) alongside $14.46B in total debt, risk/reward is balanced, justifying a disciplined Hold stance.457
Cencora, Inc. (formerly AmerisourceBergen) is a leading global pharmaceutical solutions provider centered on sourcing and distributing pharmaceuticals, medical products, and practice solutions to healthcare providers and pharmacies worldwide. The company plays a critical infrastructure role in the healthcare value chain, ensuring the daily secure delivery of brand, generic, and specialty therapies.
The company operates through two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. In fiscal 2025, U.S. Healthcare Solutions generated $290.98B in revenue (90.6% of total) and $3.57B in segment operating income, while International Healthcare Solutions generated $30.37B in revenue and $648.27M in segment operating income. Cencora is anchored by long-term customer relationships, notably Walgreens Boots Alliance (25% of revenue) and Evernorth Health Services (13% of revenue).
A severe stress scenario combines volume contraction at anchor customer Walgreens Boots Alliance with customer credit impairment and elevated balance sheet leverage following the American Oncology Network acquisition. Walgreens represents 25% of consolidated revenue and 38% of accounts receivable net of incentives, for which Cencora generally does not require collateral. If Walgreens accelerates retail store closures and reduces distribution share below 18%, domestic warehouse fixed costs would fail to absorb volume loss, compressing operating margins toward 1.1%. In the event of an anchor customer credit restructuring, bad-debt provisions against $3.13B in cash and $9.17B in invested capital would freeze operating cash flow conversion below $2.50B. Compounded by $14.46B in total debt and ~$1.7B in initial cash outlay for AON, pre-tax debt costs would rise above 5.97% and required cost of equity would elevate well beyond 7.61%, triggering severe valuation contraction.
Agreements with Walgreens and Boots UK Ltd. represented approximately 25% of consolidated revenue and 38% of accounts receivable net of incentives as of September 30, 2025. Furthermore, Cencora's August 12, 2026 Form 8-K confirmed that non-prime vendor Walgreens volume began moving outside the company starting July 1, 2026. An accelerated retail store closure program or contract downsizing by Walgreens would directly impair distribution volume and fixed-cost absorption.7
可能削弱我们投资逻辑的五项变化。
Cencora commands a Narrow economic moat rooted in irreplaceable nationwide distribution scale and efficient logistics across the United States pharmaceutical supply chain. Together with McKesson and Cardinal Health, Cencora operates as part of an entrenched wholesale triopoly that collectively distributes more than 90% of all domestic pharmaceuticals. In fiscal 2025, U.S. Healthcare Solutions generated $290.98B in revenue and $3.57B in segment operating income, demonstrating the earnings stability enabled by distributing essential therapeutics.
The primary structural source of Cencora's moat is scale advantage. Operating at thin gross margins across the wholesale drug distribution industry creates insurmountable economic barriers to prospective entrants. Replicating Cencora's capital-intensive temperature-controlled facilities, specialized handling of complex specialty drugs and GLP-1 therapies, and sophisticated regulatory tracking systems would require tens of billions in capital with no assurance of securing manufacturer volume discounts. Furthermore, long-term relationships with major anchor clients like Walgreens Boots Alliance (25% of revenue) and Evernorth Health Services (13% of revenue) provide predictable procurement volume.
Offsetting these advantages, Cencora's moat is bounded to Narrow rather than Wide due to intense customer concentration and customer bargaining leverage. With its two largest customers accounting for 38% of consolidated revenue, and Walgreens representing 38% of trade accounts receivable net of incentives, Cencora possesses limited standalone pricing flexibility. While the acquisition of American Oncology Network for $2.4B enterprise value builds out higher-margin provider network switching costs, wholesale distribution fee contracts remain subject to periodic renegotiation and payer cost-containment pressures.
Cencora generates steady economic profit in excess of its 7.04% WACC and 7.61% cost of equity, anchored by invested capital of $9.17B and segment operating income of $3.57B in U.S. Healthcare Solutions. Even with razor-thin consolidated GAAP operating margins of 0.82%, extraordinary asset velocity and negative net working capital characteristics drive robust return on invested capital.2567
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($328.59). Each row and column shows what Fair value becomes when one assumption moves.
A free-cash-flow drop test is not available in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
Specialty pharmaceutical distribution and oncology MSO capabilities accelerate following the integration of American Oncology Network. Top-line revenue compounds at 7.5% to 8.0%, gross margin expands above 3.7%, and operating margin expands toward peer levels of 1.35%. Robust free cash flow accelerates share retirements well beyond the baseline.3
A sustained acceleration in specialty distribution and successful integration of provider networks expanding operating margins toward top peers would justify moving to a higher rating band.
Results tracking in line with baseline assumptions confirm steady compounding in an entrenched oligopoly, supporting the frozen house valuation without multiple expansion.
A material earnings miss or volume deceleration driven by customer attrition would indicate deteriorating economics, warranting a lower rating band.
Cencora exhibits high earnings quality supported by exceptional cash conversion, with FY2025 operating cash flow of $3.88B and free cash flow of $3.21B substantially exceeding reported GAAP net income of $1.55B. Non-GAAP adjustments primarily reflect routine items including acquisition intangibles amortization, litigation and opioid matters, and transaction costs, while recurring distribution operations generate predictable, fee-based cash flows.56
Post-event consensus revisions have been essentially flat, with FY2027 EPS estimates moving marginally by -0.15% to $19.80 and revenue estimates adjusting by -0.32% to $351.85B. Meanwhile, reported FY2026 diluted EPS reached $13.31, indicating firm underlying operating execution despite retail volume headwinds.14
WBA accounts for approximately 25% of consolidated revenue and 38% of accounts receivable; store closures directly impact physical distribution throughput.7
Cencora demonstrates exceptional cash conversion characteristics. In fiscal 2025, operating cash flow reached $3.88B while capital expenditures were disciplined at $667.98M, generating free cash flow of $3.21B. Free cash flow conversion substantially exceeds reported GAAP net income of $1.55B, reflecting negative working capital dynamics and disciplined asset utilization. However, working capital remains sensitive to receivables timing from top customers, with Walgreens alone accounting for 38% of net accounts receivable.567
Massive inventory velocity and asset turnover generate substantial economic profit despite thin wholesale GAAP operating margins of 0.82%.
ROIC exceeds WACC. With invested capital of $9.17B as of September 30, 2025 and U.S. Healthcare Solutions operating profit of $3.57B (consolidated GAAP operating income of $2.63B), after-tax return on invested capital comfortably exceeds the company WACC of 7.04% and cost of equity of 7.61%.
| 营业收入 | US$84,754,837,000 |
|---|---|
| 营业成本 | US$81,147,602,000 |
| 毛利 | US$3,607,235,000 |
| 营业费用 | US$2,487,018,000 |
| 营业利润 | US$1,120,217,000 |
| 营业外项目及税项 | -US$356,699,000 |
| 净利润 | US$763,518,000 |
| 总资产 | US$76,590,112,000 |
|---|---|
| 现金 | US$4,356,138,000 |
| 流动资产 | US$52,239,073,000 |
| 总负债 | US$74,843,027,000 |
| 流动负债 | US$57,820,539,000 |
| 股东权益 | US$1,747,085,000 |
| 净利润 | US$1,554,169,000 |
|---|---|
| 经营现金流入 | US$3,875,120,000 |
| 折旧与摊销 | US$1,051,075,000 |
| 股份支付 | US$147,963,000 |
| 其他经营调整项 | US$1,121,913,000 |
| 经营现金流 | US$3,875,120,000 |
| 可用现金 | US$9,422,114,000 |
| 期初现金 | US$3,297,880,000 |
| 融资现金流入 | US$2,249,114,000 |
| 投资现金流出 | US$4,977,293,000 |
| 资本支出 | US$667,981,000 |
| 其他投资活动 | US$4,309,312,000 |
| 汇率影响 | US$50,272,000 |
| 期末现金 | US$4,394,549,000 |
| 投资现金流 | -US$4,977,293,000 |
| 融资现金流 | US$2,249,114,000 |
来源: SEC EDGAR · 申报日期 2025-11-25 · SEC EDGAR
| 按经营分部划分的收入 | 营业收入 | 占比 | 同比 |
|---|---|---|---|
| USHealthcare Solutions | US$2909.8亿 | 90.6% | 9.7% |
| International Healthcare Solutions | US$303.7亿 | 9.5% | 6.1% |
2026-10-22分析所采用的时点财务数据。
| 期间 | 营业收入 | EBITDA | 净利润 | 经营现金流 | 自由现金流 | 资本支出 | 折旧与摊销 | 股份支付 | 股份回购 | 已付股息 | 净债务发行 | 投资现金流 | 融资现金流 | 期初现金 | 期末现金 | 现金与投资 | 总债务 | 营业利润率 | ROIC | WACC | ROIC−WACC利差 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-09-30 | US$1531.4亿 | US$14.9亿 | US$3.6亿 | US$15亿 | US$10.4亿 | US$4.7亿 | US$4亿 | US$6220.6万 | US$3.3亿 | US$3.2亿 | — | -US$5亿 | -US$13.1亿 | US$27.4亿 | US$24.4亿 | US$24.4亿 | US$34.4亿 | 0.7% | — | 4.7% | — |
| 2018-09-30 | US$1679.4亿 | US$18.7亿 | US$16.6亿 | US$14.1亿 | US$10.7亿 | US$3.4亿 | US$4.7亿 | US$6231.6万 | US$6.4亿 | US$3.3亿 | — | -US$11.1亿 | -US$2.4亿 | US$24.4亿 | US$24.9亿 | US$24.9亿 | US$4亿 | 0.9% | — | 6.2% | — |
| 2019-09-30 | US$1795.9亿 | US$16.5亿 | US$8.6亿 | US$23.4亿 | US$20.3亿 | US$3.1亿 | US$4.6亿 | US$5887.4万 | US$6.7亿 | US$3.4亿 | — | -US$3.8亿 | -US$10.9亿 | US$24.9亿 | US$33.7亿 | US$33.7亿 | US$41.7亿 | 0.6% | — | 4.8% | — |
| 2020-09-30 | US$1898.9亿 | -US$47.3亿 | -US$34.1亿 | US$22.1亿 | US$18.4亿 | US$3.7亿 | US$3.9亿 | US$7441.1万 | US$4.2亿 | US$3.4亿 | — | -US$3.8亿 | -US$6亿 | US$33.7亿 | US$46亿 | US$46亿 | US$41.2亿 | -2.7% | — | — | — |
| 2021-09-30 | US$2139.9亿 | US$29.2亿 | US$15.4亿 | US$26.7亿 | US$22.3亿 | US$4.4亿 | US$5.1亿 | US$9959.4万 | US$8215万 | US$3.7亿 | — | -US$61.4亿 | US$19.5亿 | US$46亿 | US$30.7亿 | US$29.2亿 | US$66.8亿 | 1.1% | — | 3.7% | — |
| 2022-09-30 | US$2385.9亿 | US$31.2亿 | US$17亿 | US$27亿 | US$22.1亿 | US$5亿 | US$6.9亿 | US$9340万 | US$4.8亿 | US$3.9亿 | -US$9.2亿 | -US$3.7亿 | -US$17.5亿 | US$30.7亿 | US$35.9亿 | US$33.9亿 | US$57亿 | 1.0% | — | 5.7% | — |
| 2023-09-30 | US$2621.7亿 | US$34.2亿 | US$17.5亿 | US$39.1亿 | US$34.5亿 | US$4.6亿 | US$9.6亿 | US$1.2亿 | US$11.8亿 | US$4亿 | -US$6.2亿 | -US$26亿 | -US$22.2亿 | US$35.9亿 | US$27.5亿 | US$25.9亿 | US$47.9亿 | 0.9% | — | 6.6% | — |
| 2024-09-30 | US$2939.6亿 | US$33.7亿 | US$15.1亿 | US$34.8亿 | US$30亿 | US$4.9亿 | US$10.9亿 | US$1.5亿 | US$14.9亿 | US$4.2亿 | -US$3.9亿 | -US$6.2亿 | -US$23.3亿 | US$27.5亿 | US$33亿 | US$31.3亿 | US$43.9亿 | 0.7% | — | 5.5% | — |
| 2025-09-30 | US$3213.3亿 | US$37.5亿 | US$15.5亿 | US$38.8亿 | US$32.1亿 | US$6.7亿 | US$10.5亿 | US$1.5亿 | US$4.4亿 | US$4.4亿 | US$32亿 | -US$49.8亿 | US$22.5亿 | US$33亿 | US$43.9亿 | US$43.6亿 | US$76.6亿 | 0.8% | — | 5.6% | — |
Cencora, Inc. (COR) trades at 15.7x forward earnings against a peer median of 16.2x. Its EV/EBITDA of 13.8x compares with a peer median of 14.5x. The comparison uses 4 peers: Cardinal Health Inc., McKesson Corporation, Henry Schein Inc. and Boston Scientific Corporation, as of 2026-10-21 to 2026-10-22.
Industry benchmark datasets for capex-to-revenue and capex-to-depreciation are not available in current filings, so the cycle view is demand-led and evidence-limited. At the issuer level, capital expenditures were $667.98M in FY2025 on $321.33B in consolidated revenue (0.21% capex-to-revenue), reflecting low fixed asset intensity complemented by inorganic expansion such as the $2.4B acquisition of American Oncology Network announced October 21, 2026.6
Sustained introduction and volume adoption of complex specialty biotherapeutics, cell and gene therapies, and GLP-1 treatments expand distribution dollar fees and oncology MSO services, driving mid-to-high single-digit revenue growth and operating margin expansion.
Accelerated retail pharmacy footprint shrinkage, PBM regulatory restructuring, and drug pricing deflation reduce physical distribution volume and compress wholesale margin spreads toward 1.1%.
As one of three dominant players in the US wholesale market, Cencora is strategically positioned to capture specialty pharmaceutical growth, though customer concentration in retail pharmacy chains tempers its relative pricing power.
A moderate conviction rating and a recommended weighting of 2-3% balance Cencora's narrow economic moat and robust $3.21B free cash flow generation against acute customer concentration (Walgreens represents 25% of revenue and 38% of accounts receivable) and market pricing slightly above intrinsic fair value ($340.43 market price vs. $328.59 fair value).457
Position risk should be managed through strict customer concentration checkpoints and portfolio allocation discipline. Given that two customers represent 38% of consolidated revenue, portfolio exposure should not exceed moderate core weighting until post-AON balance sheet deleveraging progresses and retail pharmacy footprint stability is demonstrated.
Cencora provides defensive, high-ROIC compounding and consistent share buybacks, but the shares at $340.43 offer an upside of -3.5% to Fair value of $328.59, limiting capital appreciation potential over the next twelve to twenty-four months.
Cash flow stability is strong with $3.88B in operating cash flow in FY2025, but dividend yield is modest as capital return is heavily weighted to buybacks, and customer credit exposure creates tail risk.6
Trading at 15.70x forward P/E compared to peers Cardinal Health (18.31x) and McKesson (20.06x), Cencora trades at a peer discount, but this discount is warranted by acute customer concentration in Walgreens (25% revenue, 38% receivables).347
We recommend a Hold stance on Cencora, Inc.. Cencora's narrow moat, dominant domestic triopoly position, and $3.21B in annual free cash flow support steady long-term compounding. However, with market price ($340.43) slightly above intrinsic fair value ($328.59) (-3.48% implied return) and acute customer concentration in Walgreens Boots Alliance (25% revenue, 38% receivables), current valuation offers insufficient margin of safety to justify new capital allocation.457
Investors currently holding Cencora should maintain positions to benefit from specialty pharmaceutical volume growth, GLP-1 distribution, and oncology MSO expansion following the American Oncology Network acquisition. Prospective buyers should await a pullback before establishing fresh exposure.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Accelerated store closures or contractual unbundling by Walgreens Boots Alliance beyond non-prime volume reduces wholesale volume and fixed-cost absorption. Operating margins compress under volume pressure, receivables stretch working capital, and higher interest burdens from acquisition debt elevate capital costs.
Walgreens represents 38% of trade accounts receivable net of incentives, for which Cencora generally does not require collateral, against invested capital of $9.17B and cash of $3.13B. A liquidity distress event or major debt restructuring at Walgreens would trigger large bad-debt allowances, freezing operating cash flow conversion.567
Peer forward P/E multiples stand at 18.31x for Cardinal Health and 20.06x for McKesson. Cencora currently trades at a forward P/E of 15.70x and the thesis models an exit multiple of 15.0x. Legislative scrutiny into PBM spread pricing and distributor commercialization fees, combined with retail pharmacy margin pressure, risks de-rating pure-play distribution multiples.34
Total debt is $14.46B. On October 21, 2026, Cencora entered into an agreement to acquire American Oncology Network for $2.4B enterprise value with ~$1.7B initial cash outlay. Incremental debt issuance in a higher-for-longer interest rate environment elevates borrowing costs above the current pre-tax cost of debt of 5.97% and raises required cost of equity well beyond 7.61%.24
Customer credit loss provisions or working capital lockup from extended receivable collection periods.
当前：$3.88B in FY2025
触发警报：<$2.50B annually
Severe generic deflation or wholesale distribution fee spread compression across commercial drug contracts.
当前：0.82% consolidated GAAP operating margin in FY2025
触发警报：<1.00% on adjusted basis
Deceleration in domestic volume absorption indicating physical retail pharmacy contraction outpacing specialty drug gains.
当前：Mid-single-digit compounding ($290.98B in FY2025)
触发警报：<3.0% annual growth
Loss of PBM distribution volume or specialty pharmacy channel insourcing away from Cencora.
当前：13% of consolidated revenue as of FY2025
触发警报：<10% of consolidated revenue
| Federal and state legislative scrutiny into PBM spread pricing and distributor commercialization fee structures. | medium | 24-36 months | Cencora's business model relies on fee-for-service distribution and value-added commercialization services rather than drug price arbitrage, insulating operating margin spreads. |
| Balance sheet leverage expansion from physician MSO acquisitions adding debt service against $14.46B in existing total debt. | medium | 12-18 months | The acquisition values AON at $2.4B with ~$1.7B initial cash outlay, backed by robust annual free cash flow of $3.21B and committed deleveraging plans.5 |
Under the moderate discount rate, US$95.63 comes from forecast-period earnings and US$392 from the long-term value, totaling US$488.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Cencora compounds at steady mid-single-digit rates in line with the house schedule, with FY2027 revenue reaching $351.85B and adjusted EPS reaching $19.80. Operating margin normalizes along the 1.22% to 1.30% glide path, while share repurchases reduce diluted share count by 1.5% annually, supporting a fair value of $328.59.1
Wholesale triopoly peers set the efficiency benchmark for distribution scale; specialty mix shifts must offset retail fee pressure.
High cash conversion is critical to absorb ~$1.7B in transaction cash outlays and service $14.46B in total debt.4
Evernorth provides high-volume, low-credit-risk mail order and specialty stability that balances physical retail drugstore consolidation.
| $372.78B |
| $393.28B |
| $412.95B |
| Operating income | $4.29B | $4.40B | $4.73B | $5.07B | $5.37B |
| NOPAT | $3.10B | $3.18B | $3.42B | $3.67B | $3.88B |
| Residual cash after reinvestment policy | $2.64B | $2.70B | $2.91B | $3.12B | $3.30B |
| Revenue growth | 9.5% | -0.1% | 6.0% | 5.5% | 5.0% |
| Operating margin | 1.2% | 1.3% | 1.3% | 1.3% | 1.3% |
| Tax rate | 27.7% | 27.7% | 27.7% | 27.7% | 27.7% |
| Reinvestment rate | 15.0% | 15.0% | 15.0% | 15.0% | 15.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
Management maintains a balanced capital allocation strategy prioritizing share repurchases, debt service, and targeted M&A. Strong free cash flow of $3.21B in FY2025 enabled substantial share repurchases that reduced diluted share count from 195.21M in FY2025 to 190.83M shares outstanding as of October 2026, comfortably outpacing share-based compensation of $147.96M. On October 21, 2026, Cencora deployed capital into inorganic growth by signing a definitive agreement to acquire American Oncology Network for $2.4B enterprise value with ~$1.7B initial cash outlay. With total debt standing at $14.46B and a pre-tax cost of debt of 5.97%, maintaining an investment-grade rating and disciplined deleveraging remain key balance sheet priorities.
Walgreens represents 38% of accounts receivable net of incentives without collateral, compared to invested capital of $9.17B and cash of $3.13B.
Any payment stretch or credit distress at Walgreens would immediately disrupt working capital and operating cash flow.
FY2025 operating cash flow of $3.88B and FCF of $3.21B compared to GAAP net income of $1.55B.
Valuation models anchored solely on GAAP net income understate cash compounding capacity, but forward earnings must account for debt service.
U.S. Healthcare Solutions operating income grew to $3.57B on $290.98B revenue in FY2025, and FY2026 reported diluted EPS reached $13.31.
High-value specialty biopharma and provider network additions offset retail store volume attrition.
| 利润率 |
|---|
| COR | Cencora, Inc. | $65.0B | 15.7x | 0.2x | 13.8x | 96.9% | — |
| CAH | Cardinal Health Inc. | $59.6B | 18.3x | 0.2x | 15.4x | — | 1.3% |
| MCK | McKesson Corporation | $118.4B | 20.1x | 0.3x | 18.1x | — | 1.3% |
| HSIC | Henry Schein Inc. | $9.6B | 14.1x | 0.7x | 13.6x | 8.9% | 5.8% |
| BSX | Boston Scientific Corporation | $64.5B | 13.2x | 3.1x | 13.5x | 15.3% | 22.9% |
| PBM and Distribution Regulatory Scrutiny | neutral | Federal and state scrutiny into drug supply chain pricing and spread margins creates headline uncertainty, but established fee-for-service distributor contracts provide defensibility. |
| U.S. Healthcare Solutions operating margin | Operating margin compression below sustainable wholesale distributor norms | Re-examine triopoly pricing power and reduce long-term margin trajectory. |
| Annual free cash flow | Free cash flow deceleration below operational cash conversion targets | Audit working capital receivables and suspend share repurchase expectations. |
| Evernorth Health Services revenue share | Material contraction in customer revenue contribution share | Reduce cash flow projections and investigate specialty contract retention. |
